Many patients with atherosclerotic cardiovascular disease (ASCVD) receiving lipid-lowering therapy (LLT) do not achieve ≥ 50% reduction in low-density lipoprotein cholesterol (LDL-C) levels and LDL-C remains ≥ 70 mg/dl, despite recommendations made in 2018 by the American Heart Association/American College of Cardiology/Multisociety blood cholesterol guideline.

The LOGAN-CV (Clinician Engagement in Guideline-based Management of LDL ChOlesterol for Patients at HiGh Risk for a Future Atherosclerotic Cardiovascular Disease [ASCVD] EveNt) study is a prospective, 12-month study that will address a critical unmet need, evaluating the effect of a multifaceted guideline-based intervention on improving clinician behaviors and clinical outcomes in adult patients with a recent myocardial infarction (MI) and LDL-C ≥ 70 mg/dl despite receiving statins.

The multifaceted intervention includes educational modules, a cloud-based platform providing a summary of LDL-C management performance, newsletters, peer-to-peer calls, and pre- and post-intervention surveys evaluating clinicians’ knowledge, attitudes, and beliefs regarding LDL-C management.

The primary endpoint is the change in proportion of patients with LDL-C < 70 mg/dl achieved at any time during the 12-month intervention; secondary endpoints will evaluate changes in LDL-C, LLT intensification/titration, LDL-C testing, and change in clinicians’ knowledge, attitudes, and beliefs after the intervention.